Lung transplantation aims to improve health–related quality of life (HRQL) and survival. While lung function improvements are associated with these outcomes, the association between physical functioning and these outcomes is less clear. We investigated the association between changes in patient-reported physical functioning and HRQL, chronic lung allograft dysfunction (CLAD), and survival after lung transplantation. This single–center prospective cohort study analyzed 220 lung transplant recipients who completed the 15–item Lung Transplant Valued Life Activities (LT–VLA) before and repeatedly after transplant. HRQL was assessed using generic, respiratory disease–specific, and utility measures. Associations between 0.3–point changes (the minimally important difference) in LT–VLA as a time–varying predictor on HRQL, CLAD, and mortality were tested using linear regression and Cox proportional hazard models. Models were adjusted for demographics, disease diagnosis, and post–operative lung function as a time–varying covariate. Participants were 45% female and 75% White, with a mean age of 56 (±12) years. Each 0.3–point improvement in LT–VLA was associated with substantially improved HRQL across all measures (adjusted p–values <0.01). Each 0.3–point improvement in LT–VLA was associated with a 13% reduced hazard of CLAD (adjusted HR: 0.87, 95% CI: 0.76–0.99, p=0.03) and a 19% reduced hazard of mortality (adjusted HR: 0.81, 95% CI: 0.67–0.95, p=0.01). Improvements in patient–reported physical functioning after lung transplantation are associated with improved HRQL and reduced risk of CLAD and death, independent of allograft function. The simplicity of the LT–VLA suggests it could be a valuable monitoring or outcome measure in both clinical and research settings.

Jonathan P. Singer: Consulting fees from XVIVO; Scientific Advisory Board: Mallinckrodt Pharmaceuticals; DSMB: Krystal Biotech Steve R. Hays: Consulting fees from AI Therapeutics and CareDx; Scientific Advisory Board: CareDx Jasleen Kukreja: DSMB Lung Bioengineering John R. Greenland: Scientific Advisory Board and Research Funding: Theravance Biopharma Mallinckrodt Pharmaceuticals

This study was funded by NHLBI K23HL111115, U01HL163242, and U01HL145435

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Our study was approved by the UCSF Institutional Review Board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.